Trial
NCT02695160
Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Sangamo Therapeutics
Collaborators
—
Condition
Hemophilia B
Intervention
SB-FIX
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-19